Haemophilia B without inhibitors – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:28:57 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Haemophilia B without inhibitors – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effectiveness of SerpinPC for Patients with Severe Hemophilia A or B https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-serpinpc-for-patients-with-severe-hemophilia-a-or-b/ Wed, 29 Apr 2026 14:23:49 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-serpinpc-for-patients-with-severe-hemophilia-a-or-b/ This clinical trial is focused on studying the effects of a treatment called SerpinPC for individuals with Severe Hemophilia A or Moderately Severe to Severe Hemophilia B. Hemophilia is a condition where the blood does not clot properly, leading to excessive bleeding. The treatment being tested, SerpinPC, is a solution for injection that contains a modified form of a protein called human alpha-1 proteinase inhibitor. This study aims to evaluate how effective and safe SerpinPC is when given as a regular preventive treatment through subcutaneous injection, which means it is injected under the skin.

The purpose of the study is to assess the efficacy and safety of SerpinPC in people with these types of hemophilia. Participants in the study will receive the treatment over a period of time, and their health will be monitored to see how well the treatment works in reducing bleeding episodes. The study will also look at the overall health and quality of life of the participants while they are receiving the treatment.

Throughout the study, participants will be observed for any changes in their condition, and the number of bleeding episodes they experience will be recorded. The study will help determine if SerpinPC can be a beneficial treatment option for those living with Severe Hemophilia A or Moderately Severe to Severe Hemophilia B. The trial is designed to gather important information that could lead to improved care and management of these conditions in the future.

]]>